Bo Cumbo, AavantiBio CEO (file photo)

Bo Cum­bo jumps from the top com­mer­cial post at Sarep­ta to the helm of a gene ther­a­py start­up with some in­flu­en­tial back­ers, big plans and $107M

Af­ter a 7-year stretch build­ing the com­mer­cial team at Sarep­ta, long­time drug sales­man Bo Cum­bo is jump­ing to the en­tre­pre­neur­ial side of the busi­ness, tak­ing the helm of a start­up that’s got sev­er­al deep-pock­et in­vestors. And he’s not just bring­ing his ex­pe­ri­ence in sell­ing drugs.

He tells me that when he told Sarep­ta CEO Doug In­gram about it, his boss got ex­cit­ed about the ven­ture and opt­ed to jump in with a $15 mil­lion in­vest­ment from Sarep­ta to add to the launch mon­ey, along­side 3 of the busiest in­vestors in biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.